Nav: Home

A kidney disease's genetic clues are uncovered

March 06, 2017

NEW YORK, NY (March 6, 2017)--Researchers have uncovered new genetic clues to understanding IgA nephropathy (IgAN), or Berger's disease, an autoimmune kidney disease and a common cause of kidney failure. The findings are relevant to IgAN as well as other diseases with similar underlying molecular defects, such as inflammatory bowel disease and certain types of blood disease and cancer.

"Very little is known about the causes of IgAN, genetic or otherwise, so our discovery represents an important step toward developing better therapies for this disease," said lead author Krzysztof Kiryluk, MD, the Herbert Irving assistant professor of medicine at Columba University Medical Center (CUMC).

The study, conducted by researchers at CUMC and the University of Alabama at Birmingham (UAB) School of Medicine, was published last month in PLOS Genetics.

IgAN occurs when an antibody called immunoglobulin A (IgA) collects in the kidneys, causing inflammation of the glomeruli, the kidneys' filtering structures. Over time, the inflammation can hinder the kidneys' ability to filter waste from the blood. About half of patients with IgAN have progressive disease and eventually develop kidney failure. There is no cure for IgAN, but medications, along with blood pressure control, can slow disease progression.

The key molecular defect in people with IgAN is abnormal O-glycosylation of IgA antibodies. O-glycosylation--in which a sugar molecule attaches to an oxygen atom in the amino acid residue of a protein--plays a role in various physiologic processes. Studies of families have shown that problems in the O-glycosylation of IgA are common in people with IgAN and are largely genetic in origin, although the exact genes involved were unknown.

To identify genes linked to O-glycosylation problems in IgAN, Dr. Kiryluk and colleagues performed genome-wide association study (GWAS) of 2,633 people of European and East Asian ancestry, populations with high rates of the disease. All of the participants were analyzed for blood levels of galactose-deficient IgA1 (Gd-IgA1), a marker for IgAN, using a new high-throughput blood test developed by lead investigator of the study Jan Novak, PhD, associate professor of microbiology at UAB. A GWAS study of this kind had never been done before, because there was no way to efficiently measure the biomarker in such a large volume of patients.

The researchers found that variations in two genes, C1GALT1 and C1GALT1C1, were significantly more common in people with high levels of the Gd-IgA1 marker. "The genes are found on different chromosomes, but they make proteins that interact to form an enzyme critical for the proper glycosylation of IgA molecules," said Dr. Kiryluk.

To confirm that C1GALT1 and C1GALT1C1 are involved in O-glycosylation, the researchers knocked down the two genes in cells in from IgAN patients and controls. Knocking down the genes increased production of the Gd-IgA1 marker in cells from both groups.

Variations in both genes, combined, accounted for about 7 percent of the overall variability in blood levels of Gd-IgA1 in the study population. "Since approximately 50 percent of variability in Gd-IgA1 levels is due to genetic factors, this means that about 43 percent of the genetic variability is still unexplained," said Dr. Kiryluk. "We started with a relatively small study population, so explaining 7 percent of variability between individuals with the disease was a good start. As we analyze more patients, we expect that we will find more genetic variants and can begin to piece together how these variants interact with environmental factors to cause disease." A GWAS study of some 10,000 patients is now underway.
-end-
The paper is titled, "GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway." The other contributors are Yifu Li (CUMC), Zina Moldoveanu (UAB), Hitoshi Suzuki (UAB), Colin Reily UAB), Ping Hou (Peking University Institute of Nephrology, Beijing, China), Jingyuan Xie (Shanghai Jiao Tong University School of Medicine, Shanghai, China), Nikol Mladkova (CUMC), Sindhuri Prakash (CUMC), Clara Fischman (CUMC), Samantha Shapiro (CUMC), Robert A. LeDesma (CUMC), Drew Bradbury (CUMC), Iuliana Ionita-Laza (CUMC), Frank Eitner (RWTH University of Aachen, Aachen, Germany), Thomas Rauen (RWTH University of Aachen), Nicolas Maillard (University North Hospital, Saint Etienne, France), Francois Berthoux (University North Hospital), Jürgen Floege (RWTH University of Aachen), Nan Chen (Shanghai Jiao Tong University School of Medicine), Hong Zhang (Peking University Institute of Nephrology, Francesco Scolari (University of Brescia, Brescia, Italy), Robert J. Wyatt (University of Tennessee Health Sciences Center, Memphis, TN), Bruce A. Julian (UAB), and Ali G. Gharavi (CUMC).

The study was supported by grants from the National Institute for Diabetes and Digestive Kidney Diseases (K23DK090207, R03DK099564, R01DK105124, K01DK106341, R01DK078244, and R01DK082753), and the Center for Glomerular Diseases at CUMC.

The authors have declared no conflicts of interest

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. The campus that Columbia University Medical Center shares with its hospital partner, NewYork-Presbyterian, is now called the Columbia University Irving Medical Center. For more information, visit cumc.columbia.edu or columbiadoctors.org.

Columbia University Medical Center

Related Kidney Failure Articles:

Novel treatment offers kidney failure patients with rare disorder new hope
A novel treatment offers kidney failure and kidney transplant patients with a rare disorder new hope.
Study quantifies kidney failure risk in living kidney donors
Researchers have developed a risk calculator that estimates the risk of kidney failure after donation.
Potential new treatment for kidney failure in cancer patients
Kidney dysfunction is a frequent complication affecting more than 50 percent of all cancer patients, and is directly linked to poor survival.
Testing urine for particular proteins could be key to preventing kidney transplant failure
Testing for molecular markers in the urine of kidney transplant patients could reveal whether the transplant is failing and why, according to research presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
HIV+ kidney failure patients face hurdles in receiving necessary transplants
From 2001 to 2012, HIV+ kidney failure patients on the transplant waiting list were 28 percent less likely to receive a transplant compared with their HIV- counterparts.
Researchers study care for undocumented immigrants with kidney failure
By failing to provide scheduled dialysis treatments to undocumented immigrants with kidney failure, states pay higher costs for care and the patients face greater pain and psychological distress, according to a new study appearing in the latest issue of the journal JAMA Internal Medicine.
Kidney failure patients' advance directives are often inadequate
In a recent study, nearly half of kidney failure patients receiving dialysis had advance directives outlining their preferences related to end-of-life care, but only a very small minority of these directives addressed the management of dialysis.
New strategy may help prevent kidney failure in patients with diabetes
A new strategy may help halt the progression of kidney disease in patients with diabetes.
Metabolite secreted in urine may cause cognitive impairment in kidney failure patients
Retention of certain metabolites in the blood may contribute to cognitive impairment in patients with kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.
Female hormones may make women less susceptible to kidney failure than men
Researchers detected transient increases in enzymes indicative of kidney health that correlated with specific phases of the female reproductive hormone cycle.

Related Kidney Failure Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Don't Fear Math
Why do many of us hate, even fear math? Why are we convinced we're bad at it? This hour, TED speakers explore the myths we tell ourselves and how changing our approach can unlock the beauty of math. Guests include budgeting specialist Phylecia Jones, mathematician and educator Dan Finkel, math teacher Eddie Woo, educator Masha Gershman, and radio personality and eternal math nerd Adam Spencer.
Now Playing: Science for the People

#517 Life in Plastic, Not Fantastic
Our modern lives run on plastic. It's in the computers and phones we use. It's in our clothing, it wraps our food. It surrounds us every day, and when we throw it out, it's devastating for the environment. This week we air a live show we recorded at the 2019 Advancement of Science meeting in Washington, D.C., where Bethany Brookshire sat down with three plastics researchers - Christina Simkanin, Chelsea Rochman, and Jennifer Provencher - and a live audience to discuss plastics in our oceans. Where they are, where they are going, and what they carry with them. Related links:...